Scalper1 News
Bristol-Myers Squibb (BMY) said Thursday that it will file for FDA approval of nivolumab for melanoma this quarter, earlier than some on the Street expected. Nivolumab, now branded Opdivo, is Bristol’s lead drug in the much-anticipated anti-PD-1 class of cancer fighters and has achieved outstanding results in clinical trials against melanoma when combined with Bristol’s already-launched drug Yervoy. Thursday’s announcement said the initial filing Scalper1 News
Scalper1 News